Sandbox Reserved 1700
From Proteopedia
(Difference between revisions)
| Line 7: | Line 7: | ||
== Background == | == Background == | ||
| - | GCPR’s or G-Protein Coupled Receptors are a special type of protein receptor that promotes cellular signaling. Due to its structure spanning the cellular membrane, it works to transmit extracellular signals to create a change inside the cell. This is called signal transduction, and is a common way extracellular signals produce a change within cells. Some common cellular pathways that utilize GPCR’s are found in [https://proteopedia.org/wiki/index.php/Rhodopsin Rhodopsin], a protein essential for the human vision response, or the [https://proteopedia.org/wiki/index.php/Beta2_adrenergic_receptor-Gs_protein_complex_updated adrenaline fight-or-flight response]. Understanding GPCR’s and how they produce their desired intracellular signal is essential understanding essential cellular pathways, especially in their diseased states. As of 2017, there were about 475 drugs in circulation that acted on 108 GPCR targets, and at least 321 GPCR-targeting drugs were in clinical trial stages, with about 20% of them targeting novel GPCR’s. Because of the clinical relevance of GPCR’s, every new structure found, such as MRGPRX2, contributes to essential drug development to both treat disease, or modulate harmful side effects. | + | GCPR’s or G-Protein Coupled Receptors are a special type of protein receptor that promotes cellular signaling. Due to its structure spanning the cellular membrane, it works to transmit extracellular signals to create a change inside the cell. This is called signal transduction, and is a common way extracellular signals produce a change within cells. Some common cellular pathways that utilize GPCR’s are found in [https://proteopedia.org/wiki/index.php/Rhodopsin Rhodopsin], a protein essential for the human vision response, or the [https://proteopedia.org/wiki/index.php/Beta2_adrenergic_receptor-Gs_protein_complex_updated adrenaline fight-or-flight response]. Understanding GPCR’s and how they produce their desired intracellular signal is essential understanding essential cellular pathways, especially in their diseased states. As of 2017, there were about 475 drugs in circulation that acted on 108 GPCR targets, and at least 321 GPCR-targeting drugs were in clinical trial stages, with about 20% of them targeting novel GPCR’s. <ref name= "Hauser" /> Because of the clinical relevance of GPCR’s, every new structure found, such as MRGPRX2, contributes to essential drug development to both treat disease, or modulate harmful side effects. |
== GPCR Structure == | == GPCR Structure == | ||
| Line 65: | Line 65: | ||
== References == | == References == | ||
<references/> | <references/> | ||
| + | <ref name= "Hauser">PMID:29075003</ref. | ||
Revision as of 19:59, 26 March 2022
| This Sandbox is Reserved from February 28 through September 1, 2022 for use in the course CH462 Biochemistry II taught by R. Jeremy Johnson at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1700 through Sandbox Reserved 1729. |
To get started:
More help: Help:Editing |
MRGPRX2 Human Itch G-Protein Coupled Receptor (GPCR)
| |||||||||||
